Novo backs 'breakthrough' antifungal player's $60M round — with a focus on rare mold infections

Novo backs 'breakthrough' antifungal player's $60M round — with a focus on rare mold infections

Source: 
Endpoints
snippet: 

The plight of antibiotics developers has been well documented: chronically underfunded research, daunting scientific challenges, and little commercial upside even for the ones that make it to the market. But in an adjacent corner of the antimicrobial space, an antifungal player is out to paint a very different picture.